1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Network pharmacology and in vivo experiment-based strategy to investigate mechanisms of JingFangFuZiLiZhong formula for ulcerative colitis

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Ulcerative colitis (UC), a chronic inflammatory disease, often cause carcinogenesis, disability, and intestinal perforation. The JingFangFuZiLiZhong formula (JFFZLZ) shows a good effect against UC in the clinic. Hence, we aim to investigate the mechanisms between JFFZLZ and UC via network pharmacology data mining and in vivo experiments.

          Methods

          We obtained active constituents and related targets from public databases. The overlapped genes between JFFZLZ and UC targets were further analysed by enrichment analysis. The active constituents and hub targets were used to construct molecule docking analysis. We finally screened out nine hub targets and their expressions were verified in the Gene Expression Omnibus database and UC rats’ colon tissues after JFFZLZ treatment.

          Results

          The results implied that JFFZLZ mainly regulated signal transduction, metabolites production, and inflammation pathways. The expression of STAT3, CXCL8, IL6, CXCL12, TNF, TP53, and PTPN11 were both upregulated in colon tissues of UC patients and UC rats. While RELA, EGFR, and TP53 were downregulated in UC patients, but upregulated in UC rats. Furthermore, JFFZLZ could repair UC rats’ colon mucosal damage and promote the healing of ulcers via regulating the hub targets.

          Conclusion

          These results elucidated that the anti-UC effect of JFFZLZ was closely related to the inhibition of inflammatory response, inhibition of oxidative stress, and repairing colon mucosal damage through different signal pathways. The findings could contribute to a better understanding of the regulation mechanisms in JFFZLZ against UC.

          Key messages
          • JFFZLZ could reduce the inflammatory infiltration and repair UC rats’ colon mucosal damage.

          • Through the network pharmacology-based strategy and public database mining, we obtained the hub targets and key pathways between JFFZLF and UC.

          • The mechanism of JFFZLZ against UC was inhibition of inflammatory response and oxidative stress by regulating the expression of the hub targets.

          Related collections

          Most cited references56

          • Record: found
          • Abstract: found
          • Article: found

          Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease

          Crohn’s disease (CD) and ulcerative colitis (UC), the two common forms of inflammatory bowel disease (IBD), affect over 2.5 million people of European ancestry with rising prevalence in other populations 1 . Genome-wide association studies (GWAS) and subsequent meta-analyses of CD and UC 2,3 as separate phenotypes implicated previously unsuspected mechanisms, such as autophagy 4 , in pathogenesis and showed that some IBD loci are shared with other inflammatory diseases 5 . Here we expand knowledge of relevant pathways by undertaking a meta-analysis of CD and UC genome-wide association scans, with validation of significant findings in more than 75,000 cases and controls. We identify 71 new associations, for a total of 163 IBD loci that meet genome-wide significance thresholds. Most loci contribute to both phenotypes, and both directional and balancing selection effects are evident. Many IBD loci are also implicated in other immune-mediated disorders, most notably with ankylosing spondylitis and psoriasis. We also observe striking overlap between susceptibility loci for IBD and mycobacterial infection. Gene co-expression network analysis emphasizes this relationship, with pathways shared between host responses to mycobacteria and those predisposing to IBD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis

            Tofacitinib, an oral, small-molecule Janus kinase inhibitor, was shown to have potential efficacy as induction therapy for ulcerative colitis in a phase 2 trial. We further evaluated the efficacy of tofacitinib as induction and maintenance therapy.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Ulcerative colitis

              Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology affecting the colon and rectum. Multiple factors, such as genetic background, environmental and luminal factors, and mucosal immune dysregulation, have been suggested to contribute to UC pathogenesis. UC has evolved into a global burden given its high incidence in developed countries and the substantial increase in incidence in developing countries. An improved understanding of the mechanisms underlying UC has led to the emergence of new treatments. Since the early 2000s, anti-tumour necrosis factor (TNF) treatment has significantly improved treatment outcomes. Advances in medical treatments have enabled a paradigm shift in treatment goals from symptomatic relief to endoscopic and histological healing to achieve better long-term outcomes and, consequently, diagnostic modalities have also been improved to monitor disease activity more tightly. Despite these improvements in patient care, a substantial proportion of patients, for example, those who are refractory to medical treatment or those who develop colitis-associated colorectal dysplasia or cancer, still require restorative proctocolectomy. The development of novel drugs and improvement of the treatment strategy by implementing personalized medicine are warranted to achieve optimal disease control. However, delineating the aetiology of UC is necessary to ultimately achieve disease cure.
                Bookmark

                Author and article information

                Journal
                Ann Med
                Ann Med
                Annals of Medicine
                Taylor & Francis
                0785-3890
                1365-2060
                16 November 2022
                2022
                16 November 2022
                : 54
                : 1
                : 3219-3233
                Affiliations
                [a ]Dongzhimen Hospital, Beijing University of Chinese Medicine , Beijing, China
                [b ]Beijing University of Chinese Medicine , Beijing, China
                [c ]CHINA-JAPAN friendship Hospital , Beijing, China
                [d ]Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine , Beijing, China
                Author notes
                [*]

                These authors contributed equally: Mengyuan Wang, Jianan Li, and Yuzhang Yin

                Supplementary data for this article is available online at https://doi.org/10.1080/07853890.2022.2095665.

                CONTACT Shuxin Zhang zhshxincn@ 123456126.com Dongzhimen Hospital, Beijing University of Chinese Medicine , 5 Haiyuncang Rd, Dongcheng District, Beijing, 100700, P.R. China
                Xiaobin Zao  A3417@ 123456bucm.edu.cn  Dongzhimen Hospital, Beijing University of Chinese Medicine , 5 Haiyuncang Rd, Dongcheng District, Beijing, 100700, P.R. China
                Article
                2095665
                10.1080/07853890.2022.2095665
                9673803
                36382627
                8fca26db-8320-45b6-a66a-fc6afc1d9e0f
                © 2022 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.

                This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                Page count
                Figures: 7, Tables: 2, Pages: 15, Words: 7227
                Categories
                Research Article
                Pharmacology

                Medicine
                jingfangfuzilizhong formula,network pharmacology,ulcerative colitis,bioinformatics
                Medicine
                jingfangfuzilizhong formula, network pharmacology, ulcerative colitis, bioinformatics

                Comments

                Comment on this article